Skip to Content

Soriatane (acitretin) Disease Interactions

There are 8 disease interactions with Soriatane (acitretin):

Major

Acitretin (Includes Soriatane) ↔ hyperlipidemia

Severe Potential Hazard, Moderate plausibility. Applies to: Hyperlipidemia, Obesity

Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values. It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established. Care should be taken in subjects with an increased tendency to develop hypertriglyceridemia included those with disturbances of lipid metabolism, obesity, or a familial history of these conditions. Serum lipids must be more closely monitored in high-risk patients and during long-term treatment with acitretin. Dietary modifications, reduction in dose of acitretin, or drug therapy should be employed to control significant elevations of triglycerides, and if hypertriglyceridemia and low HDL levels persist, discontinuation of acitretin should be considered.

Major

Acitretin (Includes Soriatane) ↔ liver disease

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis. Therapy with acitretin is contraindicated in patients with severely impaired liver function.

Major

Acitretin (Includes Soriatane) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The use of acitretin has been associated with significant lower plasma concentrations in patients with end-stage renal failure. Therapy with acitretin is contraindicated in patients with severely impaired kidney function. It is recommended to monitor renal function as per clinical guidelines. Acitretin is not removed by hemodialysis.

Major

Retinoids (Includes Soriatane) ↔ intracranial hypertension

Severe Potential Hazard, High plausibility. Applies to: Intracranial Hypertension

The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension). Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances. Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist. If the diagnosis is confirmed, the retinoid should be discontinued permanently.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
Major

Retinoids (Includes Soriatane) ↔ psychiatric disorders

Severe Potential Hazard, Low plausibility. Applies to: Psychosis, Depression

The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation. Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression. In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.

References

  1. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
Moderate

Acitretin (Includes Soriatane) ↔ diabetes

Moderate Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus

The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control. In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis. It is recommended to monitor blood sugar levels very closely in diabetic patients.

Moderate

Acitretin (Includes Soriatane) ↔ ophthalmologic effects

Moderate Potential Hazard, Moderate plausibility. Applies to: Visual Defect/Disturbance

Ophthalmologic manifestations have been reported with the use of acitretin. It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.

Moderate

Retinoids (Includes Soriatane) ↔ liver disease

Moderate Potential Hazard, Low plausibility. Applies to: Liver Disease

The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis. Therapy with retinoids should be administered cautiously in patients with liver disease. Monitoring liver enzymes is recommended in these patients.

References

  1. "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
  2. "Product Information. Soriatane (acitretin)." Roche Laboratories, Nutley, NJ.

Soriatane (acitretin) drug interactions

There are 73 drug interactions with Soriatane (acitretin)

Soriatane (acitretin) alcohol/food interactions

There are 4 alcohol/food interactions with Soriatane (acitretin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide